November 04, 2024
Developing treatments for people with mental health conditions
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH
September 16, 2024
Topline results from Boehringer's Phase III IPF Study
September 09, 2024
Positive results reported in HER2 mutated lung cancer
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New affordability initiative with GoodRx for our biosimilar
July 17, 2024
New effort to help improve C-R-M health outcomes
June 07, 2024
Results from Phase II MASH trial presented at EASL 2024
June 01, 2024
Boehringer inhalers now available at $35 a month for eligible patients
May 13, 2024
New agreement with Quallent expands biosimilar access
May 02, 2024
Improving Access to Clinical Trials
May 01, 2024
FDA Approves Additional Formulation of Our Biosimilar
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
New FDA approval for the treatment of GPP
March 12, 2024
Update on sNDA for fibrosing ILD in children and adolescents
March 07, 2024
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
February 26, 2024
Top-line Phase II Data for treatment of MASH
November 20, 2023
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
November 10, 2023
Investigational Compound Granted FDA Orphan Drug Designation
November 06, 2023
Promising Phase II Results in Chronic Kidney Disease
November 04, 2023
AI-Driven Model Validated to Predict Risk of CKD Progression
November 01, 2023
Hip-Hop Classic “It Takes Two” Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
October 27, 2023
Boehringer Ingelheim wins 2023 Prix Galien USA
October 02, 2023
Low-WAC interchangeable biosimilar is now available
September 22, 2023
FDA Approved Treatment Option for Adults with CKD
August 28, 2023
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
August 02, 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
July 25, 2023
FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD
July 13, 2023
Interchangeable Biosimilar Now on Express Scripts® Formulary
July 04, 2023
Boehringer Ingelheim presents Effisayil™ 2 trial results
July 01, 2023
Interchangeable biosimilar now available in the U.S.
June 28, 2023
Boehringer Ingelheim and FIT Unveil Fifth Piece for The Unwearable Collection
June 23, 2023
Optum Rx Places Interchangeable Biosimilar on its Commercial Formulary
June 21, 2023
FDA approves treatment option for T2D in children 10 and older
May 22, 2023
FDA approves autoinjector pen for Interchangeable biosimilar
May 09, 2023
IL-11 inhibitor antibody clinical development launched
May 02, 2023
U.S. FDA Grants Breakthrough Therapy designation
April 01, 2023
J-Code Issued for SPEVIGO
March 29, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 08, 2023
FDA accepts Jardiance sNDA for T2D in children 10 and older
March 06, 2023
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
February 28, 2023
Boehringer Ingelheim announces new partnership to support awareness of GPP
January 20, 2023
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease.
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
Media Contacts
Head, U.S. Communications Human Pharma
900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877
Boehringer Ingelheim Animal Health USA Inc.
U.S. Communications
Phone +1 (516) 527-5456